Design purposes
Cyprotex Logo - Click to go to home page
Design purposes
Design purposes
Image title - IR FAQs
Where can I get a copy of the Financial Report and Accounts?

The Company publishes its half yearly Interim Results in August and Annual Report in March.

Cyprotex Fiscal year is 1st January to 31st December

Cyprotex adheres to theUK GAAP as its reporting standard.

All of Cyprotex's Annual and Interim Reports can be found online in the Annual and Interim Reports section of the web Investor Relations site. Should you wish to obtain a hard copy of any Financial Report, please contact the Financial Controller of Cyprotex plc at 13 - 15 Beech Lane, Macclesfield, Cheshire, SK10 2DR.

What do I do if I lose my Share Certificate?

Though most Share Certificates are handled electronically now, if any shareholder requires a replacement share certificate, this can be obtained from Capita Registrars Limited, Northern House, Woodsome Park, Fenay Bridge, Huddersfield, HD8 0LA.

What happens if a Shareholder dies?

The Beneficiaries of the will should advise Capita Registrars Limited and send a copy of the Death Certificate.

Whom do I inform if I move house or change my name?

Capita Registrars Limited, Northern House, Woodsome Park, Fenay Bridge, Huddersfield, HD8 0LA.

How can I find out what my present Shareholding is?

Contact Capita Registrars Limited, Northern House, Woodsome Park, Fenay Bridge, Huddersfield, HD8 0LA.

Can I receive corporate documents in electronic form?

Yes, they will be made available either via the Company web site or via direct Contact with the Financial Controller.

What is ADME Testing?

ADME stands for Absorption, Distribution, Metabolism and Excretion. The objective of ADME testing is to measure what happens to a compound in the human physiology. Currently ADME tests are typically done in year 6/7 of the Drug Discovery process and are a necessary provision of any clinical trial. The Cyprotex approach encourages ADME testing in years 3/4.

What products does Cyprotex sell?

Cyprotex has expertise in (1) the delivery of 20-30 In vitro ADME assays with high throughput capability for many (see below) (2) leading edge In Silico PBPK modelling capability with capacity to handle libraries of compounds based on molecular structure and other basic physical characteristics.

What are Cyprotex's USP's?

The combination of experimental data generation and In Silico prediction differentiates Cyprotex in the marketplace and provides an important competitive advantage and opportunity for customers to increase productivity.

HTS capability for In vitro assays.

In Silico software whose range PK predictive capability is supported by blue-chip Pharma as comparable to market leader.

Can access market of Pharma and Biotech Drug Discovery Organisations via wide range of market outlets i.e. Discovery Service Companies, Clinical Research Organisations, Chemogenomic Companies, Software vendors.

How many employees does Cyprotex have?

44 people

How does confidentiality work with clients?

Cyprotex fully understands the importance of IP to its customers and potential customers and generally signs a Confidentiality / Non Disclosure Agreement with clients; Cyprotex has its own suite of suitable Agreements.

Investor Relations Contact:

Russell Gibbs / Mark Warburton
+44 1625 505 100
ir@cyprotex.com
Image - design element Design purposes
Request an information pack:

  Design purposesLegal Disclaimer